Tag Archives: Mallinckrodt

August, 2018

6 August
Mallinckrodt Forms Collaborative Research Partnership with Washington University Focused on Rare Diseases

STAINES-UPON-THAMES, United Kingdom, Aug. 6, 2018 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has formed a collaborative research partnership with Washington University School of Medicine in St. Louis, a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News …
Share

26 December
Mallinckrodt to Acquire Sucampo Pharmaceuticals for $1.2 Billion

STAINES-UPON-THAMES, United Kingdom and ROCKVILLE, Md., Dec. 26, 2017 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, and Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a global biopharmaceutical company, today announced that they have entered into an agreement under which Mallinckrodt will acquire Sucampo, including its commercial and …
Share

3 November
Mallinckrodt to Acquire Ocera Therapeutics for up to $117 Million

STAINES-UPON-THAMES, United Kingdom, and REDWOOD CITY, Calif., Nov. 2, 2017 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, and Ocera Therapeutics, Inc. (NASDAQ: OCRX), today announced that they have entered into an agreement under which Mallinckrodt will acquire Ocera, a clinical stage biopharmaceutical company focused on …
Share

27 October
Studies Find Approximately Half of Patients Do Not Always Engage with Healthcare Professionals During Multiple Sclerosis Relapse

STAINES-UPON-THAMES, United Kingdom, Oct. 27, 2017 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced results from two company-sponsored surveys – the Multiple Sclerosis in America 2017 Survey (Poster P805) and a national patient survey conducted by Harris Poll (Poster P1267) – that suggest patient-reported …
Share

4 August
Mallinckrodt to Acquire InfaCare Pharmaceutical

STAINES-UPON-THAMES, United Kingdom, Aug. 4, 2017 /PR Newswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, and InfaCare Pharmaceutical Corporation today announced that they have entered into an agreement under which Mallinckrodt will acquire InfaCare, a privately held specialty pharmaceutical company focused on development and commercialization of …
Share

26 August
Mallinckrodt Sells its Nuclear Imaging Business to IBA Molecular for $690 Million

CHESTERFIELD, United Kingdom, Aug. 24, 2016 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, announced today that it has entered into a definitive agreement under which it will sell its Nuclear Imaging business to IBA Molecular (IBAM), for approximately $690 million before tax impacts, including up-front and …
Share

16 November
Mallinckrodt Pharmaceuticals Receives FDA Clearance For INOmax DS(IR) Plus MRI Device

CHESTERFIELD, United Kingdom, Nov. 16, 2015 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared INOmax DSIR® Plus MRI device for delivery of INOMAX® (nitric oxide) for inhalation during MRI procedures. The INOmax DSIR Plus MRI …
Share